Sorrento Therapeutics Inc (SRNE)
0.013
-0.01
(-35.00%)
USD |
OTCM |
Apr 25, 09:45
Sorrento Therapeutics Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 79.65M |
| April 23, 2024 | 76.89M |
| April 22, 2024 | 76.89M |
| April 19, 2024 | 79.65M |
| April 18, 2024 | 81.86M |
| April 17, 2024 | 84.06M |
| April 16, 2024 | 83.79M |
| April 15, 2024 | 86.82M |
| April 12, 2024 | 85.16M |
| April 11, 2024 | 84.61M |
| April 10, 2024 | 86.82M |
| April 09, 2024 | 78.55M |
| April 08, 2024 | 79.65M |
| April 05, 2024 | 79.65M |
| April 04, 2024 | 76.34M |
| April 03, 2024 | 74.14M |
| April 02, 2024 | 74.14M |
| April 01, 2024 | 74.14M |
| March 28, 2024 | 73.04M |
| March 27, 2024 | 73.04M |
| March 26, 2024 | 73.59M |
| March 25, 2024 | 73.59M |
| March 22, 2024 | 73.04M |
| March 21, 2024 | 73.04M |
| March 20, 2024 | 79.65M |
| Date | Value |
|---|---|
| March 19, 2024 | 74.14M |
| March 18, 2024 | 74.69M |
| March 15, 2024 | 78.55M |
| March 14, 2024 | 76.34M |
| March 13, 2024 | 78.55M |
| March 12, 2024 | 75.79M |
| March 11, 2024 | 75.24M |
| March 08, 2024 | 80.20M |
| March 07, 2024 | 80.34M |
| March 06, 2024 | 82.96M |
| March 05, 2024 | 76.89M |
| March 04, 2024 | 79.65M |
| March 01, 2024 | 79.65M |
| February 29, 2024 | 83.51M |
| February 28, 2024 | 83.51M |
| February 27, 2024 | 83.34M |
| February 26, 2024 | 84.06M |
| February 23, 2024 | 123.20M |
| February 22, 2024 | 89.30M |
| February 21, 2024 | 82.41M |
| February 20, 2024 | 85.71M |
| February 16, 2024 | 84.06M |
| February 15, 2024 | 95.09M |
| February 14, 2024 | 79.65M |
| February 13, 2024 | 82.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
72.48M
Minimum
Feb 15 2023
4.663B
Maximum
Feb 08 2021
1.058B
Average
658.19M
Median
Feb 11 2020
Enterprise Value Benchmarks
| Scilex Holding Co | 211.75M |
| AIM ImmunoTech Inc | 9.076M |
| Perspective Therapeutics Inc | 984.38M |
| Protalix BioTherapeutics Inc | 64.08M |
| Armata Pharmaceuticals Inc | 159.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -95.21M |
| Revenue (Quarterly) | 15.02M |
| Total Expenses (Quarterly) | 91.79M |
| EPS Diluted (Quarterly) | -0.17 |
| Gross Profit Margin (Quarterly) | 43.74% |
| Profit Margin (Quarterly) | -633.7% |